Skip to main content

Table 5 Association between cord blood concentrations of PFASs and risk for childhood AD in female children (n = 328)

From: Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and childhood atopic dermatitis: a prospective birth cohort study

PFASs

Number

Number of cases

Crude OR (95%CI)

Adjusted OR (95%CI)

PFOS

 Continuousa

328

74

1.05 (0.64–1.71)

1.10 (0.64–1.87)

 Q1 (< 1.80)b

82

21

1

1

 Q2 (1.80–2.47)

82

16

0.70 (0.34–1.47)

0.73 (0.33–1.61)

 Q3 (2.47–3.22)

82

16

0.70 (0.34–1.47)

0.71 (0.32–1.60)

 Q4 (≥ 3.22)

82

21

1.00 (0.50–2.02)

1.08 (0.50–2.35)

 p for trendc

  

0.85

0.74

PFOA

 Continuousa

328

74

2.05 (1.17–3.61)

2.07 (1.13–3.80)

 Q1 (< 4.94)b

82

13

1

1

 Q2 (4.94–7.00)

82

14

1.09 (0.48–2.50)

1.23 (0.52–2.93)

 Q3 (7.00–9.42)

82

20

1.71 (0.79–3.73)

1.81 (0.79–4.14)

 Q4 (≥ 9.42)

82

27

2.61 (1.23–5.52)

2.52 (1.12–5.68)

 p for trendc

  

0.004

0.01

PFNA

 Continuousa

328

74

1.92 (0.99–3.74)

2.22 (1.07–4.58)

 Q1 (< 0.50)b

82

15

1

1

 Q2 (0.50–0.66)

82

15

1.00 (0.45–2.21)

1.10 (0.46–2.62)

 Q3 (0.66–0.85)

82

19

1.35 (0.63–2.88)

1.30 (0.57–2.97)

 Q4 (≥ 0.85)

82

25

1.96 (0.94–4.07)

2.14 (0.97–4.74)

 p for trendc

  

0.04

0.05

PFDA

 Continuousa

328

74

1.14 (0.80–1.63)

1.25 (0.86–1.84)

 Q1 (< 0.25)b

82

19

1

1

 Q2 (0.25–0.38)

82

17

0.87 (0.41–1.82)

1.01 (0.46–2.23)

 Q3 (0.38–0.53)

82

12

0.57 (0.26–1.26)

0.54 (0.22–1.30)

 Q4 (≥ 0.53)

82

26

1.54 (0.77–3.08)

2.14 (1.00–4.57)

 p for trendc

  

0.35

0.13

PFUA

 Continuousa

328

74

1.15 (0.71–1.86)

1.24 (0.74–2.10)

 Q1 (< 0.29)b

82

17

1

1

 Q2 (0.29–0.41)

82

17

1.00 (0.47–2.13)

1.11 (0.49–2.50)

 Q3 (0.41–0.54)

82

19

1.15 (0.55–2.42)

1.20 (0.55–2.64)

 Q4 (≥ 0.54)

82

21

1.32 (0.64–2.73)

1.55 (0.70–3.43)

 p for trendc

  

0.41

0.28

PFDoA

 Continuousa

328

74

0.88 (0.57–1.36)

0.91 (0.57–1.46)

 Q1 (≤ 0.069)b

82

13

1

1

 Q2 (0.069–0.096)

82

27

2.61 (1.23–5.52)

3.24 (1.44–7.27)

 Q3 (0.096–0.128)

82

17

1.39 (0.63–3.08)

1.44 (0.62–3.36)

 Q4 (≥ 0.128)

82

17

1.39 (0.63–3.08)

1.63 (0.68–3.92)

 p for trendc

  

0.91

0.74

PFHxS

 Continuousa

328

74

1.59 (0.77–3.31)

1.43 (0.64–3.15)

 Q1 (≤ 0.13)b

82

14

1

1

 Q2 (0.13–0.16)

82

16

1.18 (0.53–2.60)

1.43 (0.62–3.30)

 Q3 (0.16–0.20)

82

18

1.37 (0.63–2.97)

1.29 (0.55–2.99)

 Q4 (≥ 0.20)

82

26

2.26 (1.08–4.73)

2.30 (1.03–5.15)

 p for trendc

  

0.03

0.06

PFBS

 Continuousa

328

74

1.22 (0.75–1.97)

1.23 (0.74–2.04)

 Q1 (≤ 0.037)b

82

14

1

1

 Q2 (0.037–0.047)

81

18

1.39 (0.64–3.02)

1.65 (0.70–3.84)

 Q3 (0.047–0.061)

83

23

1.86 (0.88–3.94)

1.83 (0.81–4.17)

 Q4 (≥ 0.061)

82

19

1.46 (0.68–3.17)

1.50 (0.65–3.48)

 p for trendc

  

0.25

0.35

  1. Models were adjusted for all the confounders followed, maternal age (continuous), maternal pre-pregnancy BMI (continuous), gestational week at delivery (continuous), birth weight (categorical), maternal education (categorical), paternal education (categorical), parity (categorical), mode of delivery (categorical), family history of allergic disorders (categorical), family income (categorical), maternal ethnicity (categorical), paternal smoking (categorical) and breastfeeding (categorical)
  2. aLog-transformed PFASs as continuous variables
  3. bReference category
  4. cp-Values for exposure were modeled according to the median value of each quartile